Skip to main content

Niven Ralph's Form 4 filing

Jade Biosciences, Inc. (JBIO) · filed Jul 7, 2023

Accession no.
0001415889-23-010965
Filed
Jul 7, 2023
Trade date
Jul 5, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 5 derivative transactions. Open-market sales total $38.9K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Niven RalphCIK 0001168060Officer (CHIEF SCIENTIFIC OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 5, 2023Common StockMOption exerciseAcquired+650$1.74+$1,1312,259Direct
Jul 5, 2023Common StockMOption exerciseAcquired+1,600$2.14+$3,4243,859Direct
Jul 5, 2023Common StockSSaleDisposed−2,031$17.23F2−$34,994.131,828Direct
Jul 5, 2023Common StockSSaleDisposed−219$17.87F3−$3,913.531,609Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 5, 2023Common StockMOption exerciseDisposed−450$0.00$018,708Direct
Jul 5, 2023Common StockMOption exerciseDisposed−200$0.00$012,088Direct
Jul 5, 2023Common StockMOption exerciseDisposed−200$0.00$013,894Direct
Jul 5, 2023Common StockMOption exerciseDisposed−650$0.00$042,108Direct
Jul 5, 2023Common StockMOption exerciseDisposed−750$0.00$050,732Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.68 to $17.635, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.84 to $18.17, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)